Buy & Sell Chevron Corp (CVX) – Chevron Corp Price Today
Aura AI Summary
Key Stats
- $380.59BMarket Cap
- EnergySector
- -14.06%3M Drawdown
- $420.70BEnterprise Value
- 3.73%Dividend Yield
- 93 daysTypical Hold Time
Chevron Corp (CVX) is currently valued at a market capitalization of $380.59B, with an enterprise value of $420.70B. Over the past 52 weeks, Chevron Corp has traded between a low of $135.29 and a high of $211.14, highlighting its annual price range. Over the past three months, Chevron Corp has recorded a drawdown of -14.06%, reflecting recent price volatility. Chevron Corp offers a dividend yield of 3.73%, with the most recent dividend of $1.78 paid on 17 Feb 26. On average, investors hold Chevron Corp for approximately 93 days, indicating typical investor behavior on the platform.
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Most Recent News
IREN acquires Awaken to boost global brand and marketing strategy amid expansion.
IREN Limited has acquired Awaken, a creative and media agency, to strengthen its brand awareness and marketing as it expands globally. Awaken, previously IREN's external marketing partner, will now operate in-house with key team members, including CE...
Sitryx Therapeutics to present at major healthcare investor conferences in June 2026
Sitryx Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced its management will participate in three key investor conferences in June 2026: Jefferies Global Healthcare Conference in New Y...
Regeneron shares drop 10% after Phase 3 melanoma trial misses primary endpoint.
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
